🚨 Tumor Lysis Syndrome (TLS)

Emergency Recognition, Risk Stratification & Management Protocols

🧬 Tumor Lysis Syndrome

A life-threatening oncologic emergency requiring immediate recognition and intervention

⚡ Medical Emergency 🕐 Peak Risk: 12-72 hours 🎯 Prevention Key
🏅 Updated to reflect KDIGO 2026 AKI/AKD Guideline recommendations — includes revised uric acid management (PP 3.7.2) and volume expansion without urinary alkalinization (PP 3.7.1).

🚨 CRITICAL RECOGNITION ALERT

TLS kills through hyperkalemia-induced cardiac arrest. This is a time-sensitive emergency where delay in recognition and treatment can be fatal within hours.

🚨 Immediate Action Required If:

  • Recent chemotherapy (0-7 days) in high-risk patient
  • Potassium >6.0 mEq/L with cardiac changes
  • Rising creatinine with electrolyte abnormalities
  • Oliguria or anuria post-chemotherapy
  • Neurological changes (confusion, seizures)

🧬 Definition & Pathophysiology

Tumor Lysis Syndrome (TLS) is a constellation of metabolic abnormalities that result from the rapid breakdown of tumor cells, leading to the release of intracellular contents into circulation.

💥 Cellular Destruction

Trigger: Chemotherapy, radiation, or spontaneous tumor breakdown

  • Massive cell lysis releases intracellular contents
  • High-grade malignancies most susceptible
  • Peak risk 12-72 hours post-treatment
  • Can occur spontaneously in rapidly growing tumors

🧪 Metabolic Consequences

The "Big Four" Abnormalities:

  • Hyperuricemia: Purine metabolism → uric acid
  • Hyperkalemia: Release of intracellular K+
  • Hyperphosphatemia: DNA/RNA breakdown
  • Hypocalcemia: Ca-PO4 precipitation

🫘 Kidney Injury Mechanisms

Multiple pathways leading to AKI:

  • Uric acid crystalluria: Tubular obstruction
  • Calcium-phosphate precipitation: Nephrocalcinosis
  • Volume depletion: Poor oral intake, vomiting
  • Direct cytotoxic effects: Inflammatory cascades

⚡ Life-Threatening Complications

Immediate threats to life:

  • Cardiac arrhythmias: Hyperkalemia (most common cause of death)
  • Seizures: Hypocalcemia, uremia
  • Acute kidney injury: Requiring dialysis
  • Multi-organ dysfunction: Electrolyte chaos

📊 Cairo-Bishop Classification Criteria

Gold standard for TLS diagnosis - distinguishes laboratory TLS from clinical TLS

🧪 Laboratory TLS Criteria

Two or more of the following within 3 days before or 7 days after chemotherapy:

Parameter Laboratory TLS Threshold Clinical Significance Normal Range
Uric Acid ≥8 mg/dL OR 25% increase Crystal formation, AKI risk 2.4-6.0 mg/dL
Potassium ≥6.0 mEq/L OR 25% increase Cardiac arrhythmias, death 3.5-5.0 mEq/L
Phosphorus ≥4.5 mg/dL OR 25% increase Ca-PO4 precipitation 2.5-4.5 mg/dL
Calcium ≤7 mg/dL OR 25% decrease Neuromuscular irritability 8.5-10.5 mg/dL

🏥 Clinical TLS Criteria

Laboratory TLS PLUS one or more of the following:

🫘 Acute Kidney Injury

  • Creatinine ≥1.5× upper limit of normal
  • Rising creatinine from baseline
  • Oliguria or anuria

⚡ Cardiac Arrhythmia

  • New arrhythmias
  • ECG changes (peaked T waves)
  • Sudden cardiac death

🧠 Seizures

  • Hypocalcemia-induced
  • Uremia-related
  • Electrolyte imbalance

🎯 TLS Risk Stratification

Risk assessment guides prevention strategies and monitoring intensity

🔴 HIGH RISK (15-20% incidence)

🩸 Hematologic Malignancies

  • Burkitt lymphoma (highest risk)
  • Acute lymphoblastic leukemia with WBC >100,000
  • High-grade NHL with bulky disease
  • Acute myeloid leukemia with WBC >100,000

📊 High-Risk Features

  • WBC count >100,000/μL
  • LDH >2× upper normal
  • Bulky disease (>10 cm lymph nodes)
  • Elevated baseline uric acid (>7.5 mg/dL)
Management: Prophylactic rasburicase, aggressive hydration, intensive monitoring, nephrology consultation before chemotherapy

🟡 INTERMEDIATE RISK (1-5% incidence)

🎗️ Hematologic

  • NHL with LDH <2× normal
  • ALL with WBC <100,000
  • AML with WBC 25,000-100,000
  • CLL with bulky disease

🦴 Solid Tumors

  • Germ cell tumors (testicular, ovarian)
  • Small cell lung cancer
  • Breast cancer with high proliferation
  • Neuroblastoma in children
Management: Allopurinol prophylaxis, adequate hydration, close monitoring, rasburicase if develops laboratory TLS

🟢 LOW RISK (<1% incidence)

🎗️ Hematologic

  • Multiple myeloma
  • CLL without bulky disease
  • Low-grade lymphomas
  • Hodgkin lymphoma

🦴 Most Solid Tumors

  • Colon cancer
  • Lung adenocarcinoma
  • Renal cell carcinoma
  • Most carcinomas
Management: Standard hydration, routine monitoring, consider allopurinol in high tumor burden

🧪 Laboratory Interpretation & Clinical Correlations

📈 Typical Laboratory Timeline

Parameter Peak Time Critical Values Clinical Significance Emergency Action
Uric Acid 6-12 hours >12 mg/dL AKI, crystal formation Rasburicase immediately
Potassium 12-24 hours >6.5 mEq/L Fatal arrhythmias Cardiac monitoring, stabilization
Phosphorus 24-48 hours >6.5 mg/dL Ca-PO4 precipitation Phosphate binders, avoid calcium
Calcium 24-72 hours <7.0 mg/dL Neuromuscular irritability Careful calcium replacement
Creatinine 24-72 hours 2× baseline Oliguric AKI Nephrology consultation, consider RRT

🚨 Critical Laboratory Alert Values

K+ >6.5 mEq/L: Immediate cardioprotection
Uric acid >12 mg/dL: Emergency rasburicase
PO4 >8 mg/dL: Ca-PO4 >70 high risk
Ca <7 mg/dL: Monitor for seizures
Creatinine rising: Early RRT consideration
pH <7.20: Urgent dialysis indication

⚡ Hyperkalemia Emergency Management Protocol

Hyperkalemia is the most immediately life-threatening complication of TLS

1

IMMEDIATE ASSESSMENT (0-5 minutes)

  • 12-lead ECG immediately - Look for peaked T waves, widened QRS
  • Confirm K+ level - Repeat if >6.5 mEq/L
  • Continuous cardiac monitoring
  • IV access - Large bore for emergency medications
2

MEMBRANE STABILIZATION (5-10 minutes)

  • Calcium gluconate 1-2 grams IV (10-20 mL of 10% solution)
  • Onset: 1-3 minutes, Duration: 30-60 minutes
  • May repeat every 5-10 minutes if persistent ECG changes
  • Does NOT lower K+ but prevents arrhythmias
3

POTASSIUM SHIFTING (10-30 minutes)

  • Insulin 10 units IV + D50 25 grams IV (if glucose <250 mg/dL)
  • Albuterol 10-20 mg via nebulizer (or 0.5 mg IV if available)
  • Sodium bicarbonate 50 mEq IV (if acidotic, pH <7.20)
  • Effect: 0.5-1.0 mEq/L K+ reduction, Duration: 4-6 hours
4

POTASSIUM ELIMINATION (30+ minutes)

  • Sodium zirconium cyclosilicate (Lokelma) 10 g PO (preferred)
  • Patiromer (Veltassa) 25.2 g PO (alternative)
  • Sodium polystyrene sulfonate (older agent, GI concerns)
  • Hemodialysis if K+ >7.0 mEq/L or refractory

⚠️ Special Considerations in TLS

  • Avoid calcium if PO4 >6.5 mg/dL - Risk of calcium-phosphate precipitation
  • Monitor glucose closely - Insulin can cause severe hypoglycemia
  • Serial K+ monitoring - Every 1-2 hours until <6.0 mEq/L
  • Early dialysis consideration - Don't wait for refractory hyperkalemia

💊 Rasburicase (Urate Oxidase) Therapy

Revolutionary treatment for hyperuricemia - Rapidly converts uric acid to allantoin

🧬 Mechanism of Action

  • Recombinant urate oxidase enzyme
  • Converts uric acid → allantoin
  • Allantoin 5-10× more soluble than uric acid
  • Bypasses purine catabolism pathway
  • Produces H2O2 as byproduct

🎯 Indications

  • High-risk TLS prevention
  • Treatment of established TLS
  • Uric acid >8 mg/dL with clinical TLS
  • Failed allopurinol therapy
  • Contraindication to allopurinol

💉 Dosing & Administration

  • Standard dose: 0.2 mg/kg IV
  • Maximum single dose: 7.5 mg
  • Dilute in 50 mL normal saline
  • Infuse over 30 minutes
  • Can repeat daily as needed

⚡ Clinical Effects

  • Onset: 4 hours
  • Peak effect: 4-24 hours
  • Uric acid reduction: 85-95%
  • Duration: 12-24 hours
  • Superior to allopurinol

🚨 Critical Contraindications

❌ Absolute Contraindications

  • G6PD deficiency (risk of severe hemolysis)
  • Pregnancy (safety not established)
  • Previous severe hypersensitivity

⚠️ Relative Contraindications

  • History of asthma (bronchospasm risk)
  • History of atopy (hypersensitivity risk)
  • Previous allergic reactions

🧪 G6PD Deficiency - Critical Safety Alert

  • Mechanism: H2O2 byproduct causes oxidative stress in G6PD-deficient RBCs
  • Result: Severe hemolysis, methemoglobinemia, can be fatal
  • Testing: G6PD level MUST be checked before first dose
  • Prevalence: 10-15% African males, Mediterranean populations
  • Alternative: Allopurinol + aggressive hydration if G6PD deficient

📊 Monitoring Parameters

Pre-Administration:
  • G6PD level (mandatory)
  • Baseline uric acid
  • CBC with hemolysis markers
  • Methemoglobin level
Post-Administration:
  • Uric acid at 4 hours
  • CBC for hemolysis
  • LDH, haptoglobin
  • Methemoglobin if indicated

⚠️ Lower-Risk TLS Management (KDIGO 2026 PP 3.7.2)

When rasburicase is contraindicated (G6PD deficiency) or inaccessible, xanthine oxidase inhibitors (allopurinol or febuxostat) may be used as alternative urate-lowering therapy for TLS prevention and treatment.

  • Allopurinol 300-600 mg/day: Blocks new uric acid production (does NOT break down existing uric acid)
  • Febuxostat: Alternative xanthine oxidase inhibitor, may be used when allopurinol is not tolerated
  • Key limitation: These agents only prevent NEW uric acid formation — they cannot reduce already-elevated uric acid levels like rasburicase
Important: Rasburicase remains the preferred agent for high-risk TLS (Rec 3.7.1, 1B). Xanthine oxidase inhibitors are a lower-risk alternative — not a replacement for rasburicase in high-risk patients when it is available and not contraindicated.

🩺 Renal Replacement Therapy (RRT) in TLS

Early consideration of RRT can be life-saving - Don't wait for traditional dialysis indications

🚨 Absolute Indications

  • Refractory hyperkalemia (K+ >6.5 mEq/L despite treatment)
  • Life-threatening arrhythmias
  • Severe acidosis (pH <7.20)
  • Volume overload with pulmonary edema
  • Uremic complications (encephalopathy, pericarditis)

⚠️ Relative Indications

  • Creatinine >4 mg/dL with oliguria
  • Phosphorus >8 mg/dL
  • Symptomatic hypocalcemia with high PO4
  • Uric acid >15 mg/dL despite rasburicase
  • Multiple electrolyte abnormalities

🎯 Modality Selection

  • CRRT preferred if hemodynamically unstable
  • Intermittent HD if stable and urgent correction needed
  • Higher efficiency for rapid electrolyte correction
  • Avoid rapid fluid/osmolality changes

📊 Monitoring During RRT

  • Electrolytes every 2-4 hours
  • Continuous cardiac monitoring
  • Phosphorus removal rate
  • Volume status assessment
  • Calcium-phosphate product

💡 RRT Clinical Pearls for TLS

  • Early intervention is better than late: Consider RRT when 2+ absolute indications present
  • Phosphorus is poorly dialyzed: Use phosphate-free dialysate, consider extended treatments
  • Calcium supplementation during dialysis: Monitor Ca×PO4 product carefully
  • Rebound phenomenon: Electrolytes may worsen after stopping RRT
  • Duration: Usually 2-7 days until kidney recovery and tumor response

🛡️ TLS Prevention Strategies

Prevention is superior to treatment - Risk stratification guides intervention intensity

🔴 High-Risk Prevention

  • Rasburicase 0.2 mg/kg IV - Start before chemotherapy
  • Aggressive IV crystalloid hydration: 3-4 L/day (if tolerated)
  • No urinary alkalinization (KDIGO 2026 PP 3.7.1)
  • Intensive monitoring: Q6-8h electrolytes
  • Nephrology consultation before treatment
  • Admit to monitored setting (ICU/step-down)

🟡 Intermediate-Risk Prevention

  • Allopurinol 300-600 mg daily
  • Adequate hydration: 2-3 L/day
  • Monitor electrolytes Q12h × 48h
  • Rasburicase if lab TLS develops
  • Avoid nephrotoxic agents
  • Consider inpatient monitoring

🟢 Low-Risk Prevention

  • Maintain hydration: 1.5-2 L/day
  • Monitor electrolytes at 24-48h
  • Consider allopurinol if bulky disease
  • Patient education on warning signs
  • Outpatient monitoring acceptable

💧 Volume Expansion Protocol (KDIGO 2026 PP 3.7.1)

KDIGO 2026 Update: Volume expansion should be done WITHOUT urinary alkalinization using intravenous crystalloids. Urinary alkalinization is no longer recommended as part of TLS prevention — it may worsen calcium-phosphate precipitation and has not shown benefit over crystalloid hydration alone.
🚰 Fluid Selection:
  • Intravenous crystalloids (normal saline or balanced crystalloid)
  • Avoid potassium-containing fluids
  • No sodium bicarbonate for alkalinization
🎯 Targets:
  • Urine output >2 mL/kg/hr
  • Specific gravity <1.010
  • Avoid volume overload
⚖️ Monitoring:
  • Daily weights
  • I/O balance
  • Signs of CHF

⏰ TLS Monitoring Timeline

Structured monitoring approach based on risk stratification and clinical presentation

Pre-Chemotherapy (Hours -24 to 0)
• Risk assessment and stratification • G6PD testing if rasburicase planned • Baseline labs: CBC, CMP, uric acid, LDH, phosphorus • Hydration initiation • Prophylactic therapy as indicated
0-6 Hours Post-Chemotherapy
• Continuous cardiac monitoring if high-risk • Electrolytes at 4-6 hours • Urine output monitoring • Early signs assessment • Rasburicase if indicated
6-24 Hours (Peak Risk Window)
• Electrolytes Q6-8h if high-risk • Q12h if intermediate risk • Nephrology consultation if abnormal • Aggressive intervention for lab TLS • Monitor for clinical TLS development
24-72 Hours (Critical Period)
• Peak risk for clinical complications • Q8-12h labs if stable • Daily weights and I/O • Assess for AKI development • RRT consideration if indicated
72+ Hours (Recovery Phase)
• Daily labs if improving • Q12-24h if stable • Monitor kidney recovery • Plan for discharge • Long-term nephrology follow-up

🧮 TLS Risk Assessment Calculator

Comprehensive risk stratification tool incorporating tumor factors, patient characteristics, and laboratory values

Calculating TLS risk assessment...

🎯 Essential TLS Learning Points

🚨 Emergency Recognition

  • Hyperkalemia most immediately lethal
  • Peak risk 12-72 hours post-chemo
  • Cairo-Bishop criteria for diagnosis
  • High-grade lymphomas highest risk

💊 Rasburicase Revolution

  • Converts uric acid to soluble allantoin
  • 85-95% uric acid reduction
  • Contraindicated in G6PD deficiency
  • Superior to allopurinol in high-risk

⚡ Emergency Management

  • Calcium for membrane stabilization
  • Insulin/D50 + albuterol for K+ shifting
  • Avoid calcium if PO4 >6.5 mg/dL
  • Early RRT saves lives

🛡️ Prevention Focus

  • Risk stratification guides prevention
  • Aggressive hydration essential
  • Prophylactic rasburicase in high-risk
  • Prevention superior to treatment

🩺 RRT Indications

  • Refractory hyperkalemia absolute
  • CRRT preferred if unstable
  • Early initiation better than late
  • Phosphorus poorly dialyzed

📊 Clinical Pearls

  • Laboratory vs clinical TLS distinction
  • Ca×PO4 product >70 dangerous
  • Tumor burden predicts risk
  • Multidisciplinary approach essential

📚 For Educational Purposes Only - Emergency Management Guidelines

© 2025 Andrew Bland MD - All Rights Reserved